CN102126942A - Method for synthesizing hypericin - Google Patents
Method for synthesizing hypericin Download PDFInfo
- Publication number
- CN102126942A CN102126942A CN2010106002464A CN201010600246A CN102126942A CN 102126942 A CN102126942 A CN 102126942A CN 2010106002464 A CN2010106002464 A CN 2010106002464A CN 201010600246 A CN201010600246 A CN 201010600246A CN 102126942 A CN102126942 A CN 102126942A
- Authority
- CN
- China
- Prior art keywords
- hypericin
- reaction
- synthetic method
- emodin
- described step
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940005608 hypericin Drugs 0.000 title claims abstract description 51
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 title claims abstract description 51
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 title claims abstract description 51
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 title claims abstract 19
- 238000000034 method Methods 0.000 title abstract description 10
- 230000002194 synthesizing effect Effects 0.000 title description 2
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 claims abstract description 27
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 claims abstract description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 18
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000010189 synthetic method Methods 0.000 claims abstract description 12
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000583 acetic acid Drugs 0.000 claims abstract description 9
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- YLILOANQCQKPOD-UHFFFAOYSA-N protohypericin Chemical compound C12=C(O)C=C(O)C(C(C3=C(O)C=C(C=C33)C)=O)=C2C3=C2C3=C1C(O)=CC(O)=C3C(=O)C1=C(O)C=C(C)C=C12 YLILOANQCQKPOD-UHFFFAOYSA-N 0.000 abstract description 16
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 abstract description 9
- 239000010282 Emodin Substances 0.000 abstract description 9
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 abstract description 9
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 abstract description 9
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 abstract description 9
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 abstract description 9
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 239000007791 liquid phase Substances 0.000 abstract description 4
- 230000001678 irradiating effect Effects 0.000 abstract description 2
- 230000001376 precipitating effect Effects 0.000 abstract 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 4
- 244000141009 Hypericum perforatum Species 0.000 description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000003912 environmental pollution Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及金丝桃素的合成方法,该方法包括以下步骤:(1)将大黄素和SnCl2·2H2O溶解于冰乙酸中,在升温到100-125℃后加入36-40%的浓盐酸,反应1-3个小时,冷却,得到大黄素蒽酮;(2)将大黄素蒽酮和叔丁醇钾溶解于DMF中,在微波固液相合成/萃取仪中进行反应,反应30-90分钟,冷却,得到原金丝桃素;(3)将原金丝桃素溶解于丙酮后,卤素灯照射15-24小时,浓缩,沉淀,得到金丝桃素。该方法具有操作简单、成本低、污染少、收率和纯度高等优点。The present invention relates to a synthetic method of hypericin, which comprises the following steps: (1) dissolving emodin and SnCl 2 ·2H 2 O in glacial acetic acid, adding 36-40% of Concentrated hydrochloric acid, reacted for 1-3 hours, cooled to obtain emodin anthrone; (2) dissolve emodin anthrone and potassium tert-butoxide in DMF, react in a microwave solid-liquid phase synthesis/extractor, and react 30-90 minutes, cooling to obtain protohypericin; (3) dissolving protohypericin in acetone, irradiating with halogen lamp for 15-24 hours, concentrating and precipitating to obtain hypericin. The method has the advantages of simple operation, low cost, less pollution, high yield and purity.
Description
技术领域technical field
本发明属于药物合成领域,涉及金丝桃素的合成方法。The invention belongs to the field of medicine synthesis and relates to a synthesis method of hypericin.
背景技术Background technique
金丝桃素(hypericin),即4,4,5,5,7,7-六羟基-2,2-二甲基-中位-萘并二蒽酮,为藤黄科植物贯叶连翘的带花全草经加工提取而成,对流感等病毒作用针对性强,效果显著。金丝桃素具有抗病毒、抗抑郁、镇静、抗菌消炎、创伤收敛等多种药理作用,能抑制DNA、RNA病毒,对肿瘤细胞也有一定的抑制作用。金丝桃素的多种药理作用,使其市场需求量与日俱增。由于金丝桃素在贯叶连翘全草中的含量仅有万分之四左右,目前,国内外从贯叶连翘中提取的金丝桃素在其提取物中的含量不超过1%,即便是改善提取工艺,提取、分离出来的金丝桃素的含量也不是很高,而且还会破坏大量的天然植被或占用大量耕地。为了扩大金丝桃素的药物来源,提高金丝桃素的含量,只有通过有效的化学合成方法实现这一目标。Hypericin, that is, 4,4,5,5,7,7-hexahydroxy-2,2-dimethyl-middle-naphthodianthrone, is the belt of Hypericum perforatum of Garciniaceae The whole flower is processed and extracted, and it has a highly targeted and effective effect on viruses such as influenza. Hypericin has various pharmacological effects such as antiviral, antidepressant, sedative, antibacterial and anti-inflammatory, and wound astringent. It can inhibit DNA and RNA viruses, and also has a certain inhibitory effect on tumor cells. The multiple pharmacological effects of hypericin make its market demand increasing day by day. Since the content of hypericin in the whole plant of Hypericum perforatum is only about 4/10,000, at present, the content of hypericin extracted from Hypericum perforatum in its extracts at home and abroad does not exceed 1%. Extraction process, the content of hypericin extracted and separated is not very high, and it will destroy a large amount of natural vegetation or occupy a large amount of cultivated land. In order to expand the drug source of hypericin and increase the content of hypericin, this goal can only be achieved through effective chemical synthesis methods.
中国专利申请CN1827574A公开了一种金丝桃素及其衍生物的化学合成方法。该方法包括以下步骤:1)将1,3,8-三羟基-6-甲基蒽醌溶解于分析纯冰乙酸中,然后加入含有SnCl2·2H2O的36-40%浓盐酸,在不高于125℃下反应1-4小时,冷却,得到1,3,8-三羟基-6-甲基蒽酮;2)将1,3,8-三羟基-6-甲基蒽酮与吡啶,哌啶,氮氧吡啶和FeSO4·7H2O在100-130℃下避光反应0.5-3小时,再将反应产物溶解于丙酮,用卤素灯照射12-24小时,浓缩,用正己烷溶解,过滤沉淀,得到金丝桃素。该文献公开的合成路线属于传统的合成反应过程,具有反应时间长,反应成分复杂,环境污染大,操作麻烦和产品难纯化等缺点。Chinese patent application CN1827574A discloses a chemical synthesis method of hypericin and its derivatives. The method comprises the following steps: 1) dissolving 1,3,8-trihydroxy-6-methylanthraquinone in analytically pure glacial acetic acid, then adding 36-40% concentrated hydrochloric acid containing SnCl 2 ·2H 2 O, in React at no higher than 125°C for 1-4 hours, cool to obtain 1,3,8-trihydroxy-6-methylanthrone; 2) combine 1,3,8-trihydroxy-6-methylanthrone with Pyridine, piperidine, nitridine and FeSO 4 7H 2 O reacted at 100-130°C in the dark for 0.5-3 hours, then dissolved the reaction product in acetone, irradiated with a halogen lamp for 12-24 hours, concentrated, and washed with n-hexane The alkane was dissolved, and the precipitate was filtered to obtain hypericin. The synthetic route disclosed in this document belongs to the traditional synthetic reaction process, which has the disadvantages of long reaction time, complex reaction components, large environmental pollution, cumbersome operation and difficult purification of products.
发明内容Contents of the invention
鉴于合成金丝桃素的现有技术存在的缺点,本发明的目的是提供一种成本较低,相对收率和产率高,污染环境少的金丝桃素合成方法。In view of the shortcomings of the prior art of synthesizing hypericin, the purpose of the present invention is to provide a hypericin synthesis method with low cost, high relative yield and yield, and less environmental pollution.
为了实现本发明的目的,发明人通过大量试验改进反应条件和方法,探索出了一种有效的合成金丝桃素的方法,具体技术方案如下:In order to realize the purpose of the present invention, the contriver improves reaction conditions and method through a large number of tests, has explored a kind of method of effective synthetic hypericin, and concrete technical scheme is as follows:
一种金丝桃素合成方法,包括步骤如下步骤:A kind of synthetic method of hypericin, comprises the following steps:
(1)将大黄素转化为大黄素蒽酮(1) Convert emodin into emodin anthrone
(2)将大黄素蒽酮转化为原金丝桃素(2) Convert emodin anthrone into protohypericin
(3)将原金丝桃素转化为金丝桃素(3) Convert the original hypericin into hypericin
所述步骤(2)是在微波的条件下,以叔丁醇钾作为催化剂进行大黄素蒽酮催化缩合反应。The step (2) is to carry out the catalyzed condensation reaction of emodin anthrone with potassium tert-butoxide as a catalyst under microwave conditions.
上述的金丝桃素合成方法,其中优选步骤(2)为:将大黄素蒽酮和叔丁醇钾溶解于DMF中,在微波固液相合成/萃取仪中进行反应,冷却,分离得到原金丝桃素,其中大黄素蒽酮与叔丁醇钾的摩尔比为3-5∶0.5-0.7。进一步优选步骤(2)为:将大黄素蒽酮和叔丁醇钾溶解于DMF中,在微波固液相合成/萃取仪中进行反应,冷却,分离得到原金丝桃素,其中大黄素蒽酮与叔丁醇钾的摩尔比为3-5∶0.5-0.7;且大黄素蒽酮催化缩合反应以Ar2保护,微波反应功率保持在250-550W,反应温度为130-150℃,反应时间为30-90分钟。The above-mentioned synthetic method of hypericin, wherein the preferred step (2) is: dissolving emodin anthrone and potassium tert-butoxide in DMF, reacting in a microwave solid-liquid phase synthesis/extractor, cooling, and separating to obtain the original Hypericin, wherein the molar ratio of emodin anthrone to potassium tert-butoxide is 3-5:0.5-0.7. Further preferred step (2) is: dissolving emodin anthrone and potassium tert-butoxide in DMF, reacting in a microwave solid-liquid phase synthesis/extraction apparatus, cooling, and separating to obtain protohypericin, wherein emodin anthracene The molar ratio of ketone to potassium tert-butoxide is 3-5:0.5-0.7; and the catalyzed condensation reaction of emodin anthrone is protected by Ar 2 , the microwave reaction power is kept at 250-550W, the reaction temperature is 130-150°C, and the reaction time for 30-90 minutes.
上述的金丝桃素合成方法,所述步骤(2)催化缩合反应获得的产物需经硅胶柱层析纯化,洗脱液是体积比为4∶8∶2-0.3的石油醚∶乙酸乙酯∶甲醇。In the above-mentioned synthetic method of hypericin, the product obtained by the catalytic condensation reaction in the step (2) needs to be purified by silica gel column chromatography, and the eluent is petroleum ether with a volume ratio of 4:8:2-0.3: ethyl acetate : Methanol.
上述任一一种金丝桃素合成方法,所述步骤(1)为:将大黄素和SnCl2·2H2O溶解于冰乙酸中,升温至100-125℃,然后分批加入浓盐酸,保持反应温度100-125℃,反应1-3个小时,冷却,分离得到大黄素蒽酮;其中大黄素与SnCl2·2H2O的摩尔比为1∶3.5-5,冰乙酸与浓盐酸体积比为5∶1-3。进一步优选步骤(2)为:将大黄素和SnCl2·2H2O溶解于冰乙酸中,升温至100-125℃,然后分批加入浓盐酸,保持反应温度100-125℃,反应1-3个小时,冷却,分离得到大黄素蒽酮;其中大黄素与SnCl2·2H2O的摩尔比为1∶1.5-3.5,冰乙酸与浓盐酸体积比为5∶1-3;且整个反应过程中以Ar2保护,在反应温度达到100-125℃,且出现回流现象时分批缓慢加入浓盐酸。In any one of the hypericin synthesis methods above, the step (1) is: dissolving emodin and SnCl 2 ·2H 2 O in glacial acetic acid, raising the temperature to 100-125°C, and then adding concentrated hydrochloric acid in batches, Keep the reaction temperature at 100-125°C, react for 1-3 hours, cool, and separate emodin anthrone; wherein the molar ratio of emodin to SnCl 2 2H 2 O is 1:3.5-5, and the volume of glacial acetic acid and concentrated hydrochloric acid The ratio is 5:1-3. A further preferred step (2) is: dissolve emodin and SnCl 2 ·2H 2 O in glacial acetic acid, raise the temperature to 100-125°C, then add concentrated hydrochloric acid in batches, keep the reaction temperature at 100-125°C, and react 1-3 Hours, cooled, and separated to obtain emodin anthrone; wherein the molar ratio of emodin to SnCl 2 2H 2 O was 1:1.5-3.5, and the volume ratio of glacial acetic acid to concentrated hydrochloric acid was 5:1-3; and the whole reaction process Protected by Ar 2 in the middle, when the reaction temperature reaches 100-125°C and reflux occurs, concentrated hydrochloric acid is slowly added in batches.
上述任一一种金丝桃素合成方法,所述步骤(3)为:将原金丝桃素溶解于丙酮后,卤素灯照射15-24小时,浓缩,得到金丝桃素;其中所述原金丝桃素和丙酮摩尔比为0.5-0.7∶3-10。进一步优选步骤(2)为:将原金丝桃素溶解于丙酮后,Ar2保护,并且将Ar2通入液面以下,卤素灯照射15-24小时,浓缩,得到金丝桃素;其中所述原金丝桃素和丙酮摩尔比为0.5-0.7∶3-10。Any one of the above hypericin synthesis methods, the step (3) is: after dissolving the original hypericin in acetone, irradiating with a halogen lamp for 15-24 hours, and concentrating to obtain hypericin; wherein the The molar ratio of protohypericin and acetone is 0.5-0.7: 3-10. Further preferred step (2) is: after the original hypericin is dissolved in acetone, Ar 2 is protected, and Ar 2 is introduced below the liquid level, irradiated by a halogen lamp for 15-24 hours, and concentrated to obtain hypericin; wherein The molar ratio of protohypericin to acetone is 0.5-0.7:3-10.
与现有技术相比,本发明的金丝桃素合成方法具有如下有益的技术效果:发明人创造性地以叔丁醇钾为强碱催化剂催化大黄素蒽酮的缩合反应,使得制备金丝桃素的操作简单,制备成本较低,相对收率和纯度更高,环境污染少,取得到了较为理想的效果。Compared with the prior art, the hypericin synthesis method of the present invention has the following beneficial technical effects: the inventor creatively uses potassium tert-butoxide as a strong base catalyst to catalyze the condensation reaction of emodin anthrone, making the preparation of hypericin The operation of the element is simple, the preparation cost is low, the relative yield and purity are higher, the environmental pollution is less, and a relatively ideal effect has been obtained.
具体实施方式Detailed ways
以下是本发明的具体实施例,对本发明的技术方案做进一步作描述,但是本发明的保护范围并不限于这些实施例。凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。The following are specific examples of the present invention, and further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these examples. All changes or equivalent substitutions that do not depart from the concept of the present invention are included in the protection scope of the present invention.
下述实施例中所用方法如无特别说明均为常规方法。The methods used in the following examples are conventional methods unless otherwise specified.
现用本发明的方法人工合成金丝桃素,具体实例包括以下步骤:Now use the method artificial synthesis hypericin of the present invention, concrete example comprises the following steps:
(1)将大黄素转化为大黄素蒽酮(1) Convert emodin into emodin anthrone
取大黄素2g(7.4mmol),加入冰乙酸120mL中,Ar2保护,搅拌下加入SnCl2·2H2O2.8g(12.4mmol),将混合物开始加热,反应温度达到115℃,开始出现回流现象。在110℃左右,逐滴加浓盐酸48mL,加毕,回流反应2h(TLC跟踪)。放置冷却后,用布氏漏斗过滤,残基用去离子水洗至中性,真空干燥后称重得到大黄素蒽酮1.766mg,产率93%。Take 2 g (7.4 mmol) of emodin, add it to 120 mL of glacial acetic acid, protect it with Ar 2 , add SnCl 2 2H 2 O 2.8 g (12.4 mmol) under stirring, start heating the mixture, the reaction temperature reaches 115 °C, and reflux begins to appear . At about 110°C, 48 mL of concentrated hydrochloric acid was added dropwise, and after the addition was complete, the reaction was refluxed for 2 h (TLC tracking). After standing to cool, filter with a Buchner funnel, wash the residue with deionized water until neutral, vacuum dry and weigh to obtain 1.766 mg of emodin anthrone with a yield of 93%.
TLC跟踪反应历程时,每隔半个小时,吸取20μL反应液,加入适量无水乙醇令其完全溶解,制备样品溶液。然后精确称取大黄素蒽酮1mg加无水乙醇溶解,用移液器吸出,移至25mL容量瓶中,用无水乙醇洗涤多次,加无水乙醇定溶至25mL,制备原料溶液。将制备好的反应液与大黄素蒽酮乙醇溶液点于薄层层析板上,选用氯仿∶甲醇的体积比为3∶1作为展开剂,观察反应体系中反应物黄色斑点与生成物荧光斑点的变化,以此为指标来判断反应进行的程度。When tracking the reaction process by TLC, draw 20 μL of the reaction solution every half hour, add an appropriate amount of absolute ethanol to dissolve it completely, and prepare a sample solution. Then accurately weigh 1mg of emodin anthrone and add absolute ethanol to dissolve it, suck it out with a pipette, transfer it to a 25mL volumetric flask, wash with absolute ethanol several times, add absolute ethanol to dilute to 25mL, and prepare a raw material solution. Spot the prepared reaction solution and emodin anthrone ethanol solution on a thin-layer chromatography plate, choose chloroform:methanol with a volume ratio of 3:1 as the developer, and observe the yellow spots of the reactants and the fluorescent spots of the products in the reaction system The change is used as an indicator to judge the extent of the reaction.
(2)将大黄素蒽酮转化为原金丝桃素(2) Convert emodin anthrone into protohypericin
取大黄素蒽酮1.024g(4mmol)和0.062g(0.55mmol)叔丁醇钾溶解于40mL DMF(N,N-二甲基甲酰胺)中,磁力搅拌,在微波固液相合成/萃取仪中进行反应,反应之前通入Ar2,排尽反应瓶内的空气。设置反应温度为145℃,反应功率为450W,反应时间为40mim,开始反应。反应完后待其冷却到室温,加入去离子水。加入2mol盐酸,调节溶液pH值为2,用布氏漏斗过滤,沉淀用冷水洗至中性,真空干燥。经硅胶柱层析柱上洗脱,洗脱液(石油醚∶乙酸乙酯∶甲醇=4∶8∶0.9),得到原金丝桃素0.544mg,收率53.9%Get 1.024g (4mmol) of emodin anthrone and 0.062g (0.55mmol) of potassium tert-butoxide dissolved in 40mL of DMF (N,N-dimethylformamide), magnetic stirring, in the microwave solid-liquid phase synthesis/extraction apparatus The reaction was carried out in , and Ar 2 was passed through before the reaction, and the air in the reaction bottle was exhausted. Set the reaction temperature to 145°C, the reaction power to 450W, and the reaction time to 40mim to start the reaction. After the reaction, it was cooled to room temperature, and deionized water was added. Add 2 mol hydrochloric acid to adjust the pH value of the solution to 2, filter it with a Buchner funnel, wash the precipitate with cold water until neutral, and dry it in vacuum. After elution on a silica gel column chromatography column, the eluent (petroleum ether: ethyl acetate: methanol = 4:8:0.9) obtained 0.544 mg of prohypericin, with a yield of 53.9%
(3)将原金丝桃素转化为金丝桃素(3) Convert the original hypericin into hypericin
将原金丝桃素170mg(0.33mmol)溶解于500mL丙酮后,Ar2保护,在500瓦的卤素灯下照射24小时。反应完成后,旋转蒸发溶剂至5mL。真空干燥后称重得到产物。将上述所得产物经硅胶柱层析柱上洗脱,洗脱液(石油醚∶乙酸乙酯∶甲醇=4∶8∶0.5),得到金丝桃素150mg,收率95%。(含量为≥98.5%)。Protohypericin 170 mg (0.33 mmol) was dissolved in 500 mL of acetone, protected by Ar 2 and irradiated under a 500-watt halogen lamp for 24 hours. After the reaction was complete, the solvent was rotovapped to 5 mL. After vacuum drying, the product was weighed. The product obtained above was eluted on a silica gel column chromatography, and the eluent (petroleum ether: ethyl acetate: methanol = 4:8:0.5) was used to obtain 150 mg of hypericin with a yield of 95%. (content is ≥ 98.5%).
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010600246 CN102126942B (en) | 2010-12-22 | 2010-12-22 | Synthetic method of hypericin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010600246 CN102126942B (en) | 2010-12-22 | 2010-12-22 | Synthetic method of hypericin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102126942A true CN102126942A (en) | 2011-07-20 |
CN102126942B CN102126942B (en) | 2013-10-23 |
Family
ID=44265263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010600246 Expired - Fee Related CN102126942B (en) | 2010-12-22 | 2010-12-22 | Synthetic method of hypericin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102126942B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103274920A (en) * | 2013-06-14 | 2013-09-04 | 西北农林科技大学 | Efficient hypericin synthesizing method initiated by monochromatic light |
CN108084065A (en) * | 2017-11-21 | 2018-05-29 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of hypericin derivative and its preparation method and application |
CN108863741A (en) * | 2017-05-11 | 2018-11-23 | 上海凯伟化工科技有限公司 | A kind of synthetic method of hypericin |
CN111138262A (en) * | 2020-01-13 | 2020-05-12 | 成都金石缘科技有限公司 | Hypericin synthesis method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1827574A (en) * | 2006-04-19 | 2006-09-06 | 中国农业科学院兰州畜牧与兽药研究所 | Chemical synthesis method of hypericin and its derivatives |
-
2010
- 2010-12-22 CN CN 201010600246 patent/CN102126942B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1827574A (en) * | 2006-04-19 | 2006-09-06 | 中国农业科学院兰州畜牧与兽药研究所 | Chemical synthesis method of hypericin and its derivatives |
Non-Patent Citations (3)
Title |
---|
STEFAN AIGNER ET AL.: "A microwave-assisted synthesis of phenanthroperylene quinones as exemplified with hypericin", 《MONATSHEFTE FÜR CHEMIE》 * |
汤媛 等: "金丝桃素的合成工艺改进", 《合成化学》 * |
汤媛 等: "金丝桃素研究进展", 《医药导报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103274920A (en) * | 2013-06-14 | 2013-09-04 | 西北农林科技大学 | Efficient hypericin synthesizing method initiated by monochromatic light |
CN103274920B (en) * | 2013-06-14 | 2014-12-17 | 西北农林科技大学 | Efficient hypericin synthesizing method initiated by monochromatic light |
CN108863741A (en) * | 2017-05-11 | 2018-11-23 | 上海凯伟化工科技有限公司 | A kind of synthetic method of hypericin |
CN108084065A (en) * | 2017-11-21 | 2018-05-29 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of hypericin derivative and its preparation method and application |
CN108084065B (en) * | 2017-11-21 | 2020-06-16 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of hypericin derivative and its preparation method and application |
CN111138262A (en) * | 2020-01-13 | 2020-05-12 | 成都金石缘科技有限公司 | Hypericin synthesis method |
Also Published As
Publication number | Publication date |
---|---|
CN102126942B (en) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102126942B (en) | Synthetic method of hypericin | |
CN106046093A (en) | Synthesizing method of lithocholic acid | |
CN110128382B (en) | Preparation method and application of phellinus igniarius seed extract | |
CN102180782B (en) | Method for synthesizing hypericin | |
CN105237503A (en) | Method for preparing baicalein | |
CN105218499B (en) | A kind of method for preparing scutellarin aglycon | |
CN108358913A (en) | A kind of green synthesis process of rotundine sulfate | |
CN101519393A (en) | Novel method for preparing Scopoletin | |
CN101348411B (en) | Preparation of 2-alkyl anthracene derivative | |
CN106008499B (en) | A kind of method for preparing CDK46 kinase inhibitors Pa Boxini | |
CN111362943A (en) | Preparation method of entecavir intermediate N4 | |
CN106946831B (en) | A kind of 2-aryl-3-(difluoroalkyl) flavonoids and preparation method thereof | |
CN101928252B (en) | Preparation method of 3-methyl-2-ethanol based quinoxaline | |
US11208419B2 (en) | Phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof | |
CN100564340C (en) | (2E, 4E)-preparation method of 2-methyl-6-oxo-2 | |
CN109651121B (en) | Synthetic method of Robtein | |
CN109694311B (en) | A kind of synthetic method of isoliquiritigenin | |
CN106543208A (en) | Copper chloride (II) chelate and its synthetic method and application with 1 pyridine β carbolines as part | |
CN106554362A (en) | A kind of copper chloride (II) chelate and its synthetic method and application with 1 pyridine β carbolines as part | |
CN111732501A (en) | A kind of method for preparing guaiazulene aldehyde dimer in two steps | |
CN115181112B (en) | Synthesis of 3,4-diketone Derivatives of 6-Bromocyclo-Epimedium Chroman and Its Antitumor Application | |
CN101580499B (en) | Reaction system and method for generating flavanone by cyclization of 2'-hydroxy chalcone | |
CN112457243B (en) | Synthesis method of 7-bromo-5-methoxyquinoline | |
CN115073485B (en) | 3-aryl-7, 8-pyranocoumarin derivative, and preparation method and application thereof | |
CN106518825B (en) | A kind of chemoselective monomethylation method of coumarin catechol compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUBEI SHINREZING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUBEI INDUSTRY UNIVERSITY Effective date: 20140519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430068 WUHAN, HUBEI PROVINCE TO: 430079 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140519 Address after: 430079 No. 666, hi tech Avenue, East Lake hi tech Development Zone, Hubei, Wuhan Patentee after: Hubei Shinrezing Pharmaceutical Co., Ltd. Address before: 430068 Wuchang, Hubei Province, South Lake, Li Jia Dun special No. 1 Patentee before: Hubei Industry University |
|
ASS | Succession or assignment of patent right |
Owner name: LIU MINGXING Free format text: FORMER OWNER: HUBEI SHINREZING PHARMACEUTICAL CO., LTD. Effective date: 20140529 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430079 WUHAN, HUBEI PROVINCE TO: 430068 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140529 Address after: 430068 College of food and pharmaceutical engineering, Ministry of light industry, Hubei University of Technology, Hongshan District, Wuhan, Hubei Patentee after: Liu Mingxing Address before: 430079 No. 666, hi tech Avenue, East Lake hi tech Development Zone, Hubei, Wuhan Patentee before: Hubei Shinrezing Pharmaceutical Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: WUHAN MAIDESEN MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIU MINGXING Effective date: 20150217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430068 WUHAN, HUBEI PROVINCE TO: 430079 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150217 Address after: 430079 No. 666, hi tech Avenue, East Lake hi tech Development Zone, Hubei, Wuhan Patentee after: Wuhan Maidesen Medical Technology Co.,Ltd. Address before: 430068 College of food and pharmaceutical engineering, Ministry of light industry, Hubei University of Technology, Hongshan District, Wuhan, Hubei Patentee before: Liu Mingxing |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200121 Address after: 430000, building, B, C and D District, Wuhan hi tech Avenue, East Lake Development Zone, Wuhan, Hubei Province, B1 Patentee after: Wuhan medical Polytron Technologies Inc Address before: 430079 No. 666, hi tech Avenue, East Lake hi tech Development Zone, Hubei, Wuhan Patentee before: Wuhan Maidesen Medical Technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 Termination date: 20201222 |
|
CF01 | Termination of patent right due to non-payment of annual fee |